CIBC Asset Management’s Myriad Genetics MYGN Stock Holding History

CIBC Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,993	Closed	-$208K	–	1084
2023 Q2	$208K	Hold	8,993	–	–	﹤0.01%	952
2023 Q1	$209K	Buy	+8,993	New	+$183K	﹤0.01%	923
2021 Q4	–	Sell	-8,927	Closed	-$288K	–	1580
2021 Q3	$288K	Buy	8,927 +330	+4%	+$11K	﹤0.01%	1045
2021 Q2	$263K	Hold	8,597	–	–	﹤0.01%	1083
2021 Q1	$262K	Buy	+8,597	New	+$244K	﹤0.01%	1035
2020 Q4	–	Sell	-10,190	Closed	-$133K	–	1260
2020 Q3	$133K	Buy	10,190 +72	+0.7%	+$911	﹤0.01%	1048
2020 Q2	$115K	Hold	10,118	–	–	﹤0.01%	1028
2020 Q1	$145K	Hold	10,118	–	–	﹤0.01%	911
2019 Q4	$276K	Buy	+10,118	New	+$278K	﹤0.01%	907
2017 Q4	–	Sell	-8,559	Closed	-$310K	–	1086
2017 Q3	$310K	Buy	8,559 +108	+1%	+$3.08K	﹤0.01%	796
2017 Q2	$218K	Buy	+8,451	New	+$179K	﹤0.01%	891

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIBC Asset Management's MYGN Position: Q3 2023 in Review

CIBC Asset Management sold out of Myriad Genetics (MYGN) in Q3 2023, closing a stake of 8,993 shares — an estimated $208K sold.

CIBC Asset Management first reported a position in MYGN in Q2 2017 and held it in 11 quarters. The position peaked at $310K in Q3 2017. 186 funds tracked by Wall St. Rank hold MYGN as of Q3 2023.

CIBC Asset Management reported no remaining Myriad Genetics position as of Q3 2023 after selling out during the quarter.
CIBC Asset Management sold 8,993 Myriad Genetics shares in Q3 2023, an estimated $208K.
CIBC Asset Management first reported a position in Myriad Genetics in Q2 2017 and held it in 11 quarters.
CIBC Asset Management's Myriad Genetics position peaked at $310K in Q3 2017.
186 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2023.

Based on CIBC Asset Management's 13F filing for Q3 2023, filed 30 Oct 2023.